Why Is CSL (ASX:CSL) Launching Its New Flu Vaccine First In The UK?

Why Is CSL (ASX:CSL) Launching Its New Flu Vaccine First In The UK? Bailey Pemberton Tue, September 22, 2026 at 8:18 PM EDT 2 min read CSL.AX -0.82% CSL (ASX:CSL) has secured a multi-year Advance Purchase Agreement extension with the UK government for its Aujemflu vaccine.

The UK will be the first country to commercially launch CSL Seqirus' adjuvanted, trivalent cell-based influenza vaccine Aujemflu.

The agreement highlights the role of CSL's UK manufacturing hub in supporting national pandemic preparedness and large-scale flu vaccine supply.

The Aujemflu launch and UK purchase extension only capture part of what this move could mean for CSL's wider vaccine position. Take a look at 1 warning sign we have identified for CSL.

Explore other vaccine and broader healthcare stocks that could benefit from similar government partnerships and long-term supply agreements through our screener containing 16 high quality undiscovered gems .